In fact, the therapeutic effects that we observed in the setting of higher ACTA1-CUGexp RNA content suggests the potential for an even greater clinical benefit of fiber type transition in DM1 patients if DMPK-CUGexp expression remains stable. This evidence concerns the gene ACTA1 and myotonic dystrophy type 1.